Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

Citation
Shao SC, Chang K, Hung M, et al. Cardiovasc Diabetol 2019;18:120.